Post-Grant Proceedings Are Important For Biosimilars
Patent certainty is a major goal of generic drug manufacturers — whether small molecule or biologic. However, compared to their small molecule brethren, biosimilar developers potentially face a much more complicated...To view the full article, register now.
Already a subscriber? Click here to view full article